Patents by Inventor Kazuko Matsuda

Kazuko Matsuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11925625
    Abstract: A method of treating chemical-induced lung injury in a subject in need thereof includes administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: March 12, 2024
    Assignee: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Federico Carlos Aréjola Gaeta
  • Publication number: 20240016729
    Abstract: A injectable pharmaceutical compositions consists of a buffered aqueous solution comprising (a) about 5% w/v to about 15% w/v sulfobutylether-?-cyclodextrin (SBE-?-CD), and about 0.05% w/v to about 0.5% w/v ibudilast, or (b) about 5% w/v to about 25% w/v polyoxyl castor oil, and about 1% w/v to about 5% w/v ibudilast.
    Type: Application
    Filed: July 12, 2023
    Publication date: January 18, 2024
    Applicant: MediciNova, Inc.
    Inventors: Kazuko MATSUDA, Federico Carlos Aréjola Gaeta, Yuichi IWAKI
  • Patent number: 11865214
    Abstract: This disclosure is directed to ibudilast higher dosage oral formulations, such as tablet or capsule formulations, and the corresponding methods of treatment.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: January 9, 2024
    Assignee: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Federico Carlos Aréjola Gaeta
  • Publication number: 20230285367
    Abstract: Disclosed is a method of treating post-COVID condition(s) in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
    Type: Application
    Filed: January 31, 2023
    Publication date: September 14, 2023
    Applicant: MediciNova, Inc.
    Inventor: Kazuko Matsuda
  • Publication number: 20230116096
    Abstract: A method of preventing metastasis of a cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
    Type: Application
    Filed: July 25, 2022
    Publication date: April 13, 2023
    Applicant: MEDICINOVA, INC.
    Inventors: Kazuko Matsuda, Federico Carlos Aréjola Gaeta
  • Publication number: 20230090534
    Abstract: Disclosed herein are compositions and methods for treating glioblastoma in a patient in need thereof by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor.
    Type: Application
    Filed: September 19, 2022
    Publication date: March 23, 2023
    Applicant: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Michael Vogelbaum, Justin Lathia
  • Publication number: 20230037014
    Abstract: A method of preventing metastasis of a cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
    Type: Application
    Filed: July 25, 2022
    Publication date: February 2, 2023
    Applicants: MediciNova, Inc., The Trustees of Columbia University in the City of New York
    Inventors: Kazuko Matsuda, Grazia Ambrosini, Gary K. Schwartz, Alex J. Rai
  • Publication number: 20220387364
    Abstract: Described herein are methods for decreasing triglyceride synthesis and/or decreasing triglyceride accumulation in the liver of a subject, wherein the methods comprise administering to the subject a compound of Formula (I): a metabolite thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 26, 2022
    Publication date: December 8, 2022
    Applicant: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Masatsune Ogura
  • Patent number: 11446283
    Abstract: Methods and dosing regimens for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof and at least one or more other therapeutic agent.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: September 20, 2022
    Assignee: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Kerrie McDonald
  • Publication number: 20220241252
    Abstract: A method of treating chemical-induced lung injury in a subject in need thereof includes administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
    Type: Application
    Filed: January 27, 2022
    Publication date: August 4, 2022
    Applicant: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Federico Carlos Aréjola Gaeta
  • Publication number: 20220168283
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Application
    Filed: July 2, 2021
    Publication date: June 2, 2022
    Applicant: MediciNova, Inc.
    Inventors: Michael E. Kalafer, Kenneth W. LOCKE, Kazuko MATSUDA, Richard E. GAMMANS
  • Patent number: 11278531
    Abstract: The present disclosure relates generally to methods for treating neurodegenerative diseases, including their progressive forms. In particular, the present disclosure pertains to methods of treating or preventing neurodegenerative diseases, including their progressive forms and their associated symptoms by administering a combination of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) and riluzole, or pharmaceutically acceptable salts of one or both thereof.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: March 22, 2022
    Assignee: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Yuichi Iwaki
  • Patent number: 11154540
    Abstract: This disclosure is directed to methods of treating ophthalmic disease/disorder or injury associated with neurodegenerative disease/disorder, such as progressive multiple sclerosis, or a neuro-ophthalmologic disorder in human patients using ibudilast.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: October 26, 2021
    Assignee: MediciNova, Inc.
    Inventor: Kazuko Matsuda
  • Publication number: 20210308109
    Abstract: Disclosed is a method of reducing plasma level of macrophage migratory inhibitory factor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
    Type: Application
    Filed: April 5, 2021
    Publication date: October 7, 2021
    Applicant: MediciNova, Inc.
    Inventors: Yuichi IWAKI, Kazuko MATSUDA
  • Patent number: 11083713
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: August 10, 2021
    Assignee: MediciNova, Inc.
    Inventors: Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
  • Publication number: 20210177812
    Abstract: Methods of suppressing myeloid-derived suppressor cells (MDSCs), reducing immune suppression, reducing regulatory T-cell count and increasing CD4+ T-cell count in cancer patients using ibudilast.
    Type: Application
    Filed: July 31, 2020
    Publication date: June 17, 2021
    Applicant: MediciNova, Inc.
    Inventor: Kazuko Matsuda
  • Publication number: 20210085613
    Abstract: This disclosure is directed to ibudilast higher dosage oral formulations, such as tablet or capsule formulations, and the corresponding methods of treatment.
    Type: Application
    Filed: September 21, 2020
    Publication date: March 25, 2021
    Applicant: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Federico Carlos Aréjola Gaeta
  • Patent number: 10946071
    Abstract: This disclosure is directed to methods of alleviating the negative effects of, treating, or slowing the progression of progressive multiple sclerosis in human patients using ibudilast and interferon-beta.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: March 16, 2021
    Assignee: MediciNova, Inc.
    Inventor: Kazuko Matsuda
  • Publication number: 20210023063
    Abstract: Methods and dosing regimens for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof and at least one or more other therapeutic agent.
    Type: Application
    Filed: July 10, 2020
    Publication date: January 28, 2021
    Applicant: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Kerrie McDonald
  • Publication number: 20210000804
    Abstract: The present disclosure relates generally to methods for treating neurodegenerative diseases, including their progressive forms. In particular, the present disclosure pertains to methods of treating or preventing neurodegenerative diseases, including their progressive forms and their associated symptoms by administering a combination of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) and riluzole, or pharmaceutically acceptable salts of one or both thereof.
    Type: Application
    Filed: June 18, 2020
    Publication date: January 7, 2021
    Applicant: MEDICINOVA, INC.
    Inventors: Kazuko Matsuda, Yuichi Iwaki